ceptors are inactivated by the a 1ating agent N-ethylmaleimide when occupied by ,-adrenergic agonists but not when occupied by antagonists or when unoccupied. A time-dependent decrease of the number of receptor sites is observed. Inactivation affects 45-0% of the sites, regardless of the agonist or N-ethylmaleimide concentration. The guanine nucleotides GTP and 5'-guanylyl imidodiphosyhate effectively protect-the receptors against agonist-mediated inactivation by N-ethylmaleimide. Protection by ATP necessitates a 16fold higher concentration; 10 mM NaF is ineffective. The guanine nucleotide effect is reversible and occurs via interaction with N-ethylmaleimide-insensitive sites. These observations establish that guanine nucleotide sites interact with and cause structural modification of the agonist-occupied P-adrenergic receptors in turkey erythrocyte membranes.
The /3-adrenergic receptor and the adenylate cyclase enzyme are distinct components of the plasma membrane, separable from each other by gel filtration (1) and affinity chromatography (2) . Additional evidence suggests the existence of a third component through which guanine nucleotides allow activation of adenylate cyclase. These guanine nucleotide binding sites are distinct and separable from both the receptor and the adenylate cyclase catalytic unit (3) (4) (5) . In addition, guanine nucleotides regulate f3-adrenergic receptors: GTP and analogs such as 5'-guanylyl imidodiphosphate (p[NH] ppG) decrease the binding affinity of agonists for the fl-adrenergic receptors in glioma and lymphoma cell lines (6, 7) and frog erythrocytes (8) . The agonist-induced desensitization of the frog erythrocyte f3-adrenergic receptors can readily be reversed by addition of guanine nucleotides (9) , via a shift from a high-affinity catecholamine-receptor complex to a low-affinity rapidly dissociable complex (10) .
In contrast to these observations, guanine nucleotide regu- 
RESULTS
The specific (-)-[3HJdihydroalprenolol binding sites on turkey erythrocyte membranes have been identified as f3-adrenergic receptors (2) . Binding occurs to a single class of noncooperative sites with an equilibrium dissociation constant (Kd) of 8 i 2 X 10-9 M; it shows rapid association/dissociation kinetics (16) .
Pretreatment of the membranes with either 50 jIM N-ethylmaleimide or 50 nM (-)-isoproterenol for 15 mmi at 30'C did not affect subsequent binding of 10 nM (-)-[3H]dihydroalprenolol. However, pretreatment with both compounds in combination gave rise to a time-dependent fall in the binding activity ( Fig. 1) . This fall reflects a decrease in the number of receptor sites. Because the affinity of (-)[3H]dihydroalprenolol for the remaining sites was not affected (Fig. 2) , the number of receptor sites could be monitored by binding of a subsaturation concentration of (-)-[3H]dihydroalprenolol (10 nM) .
In a previous report (14) , it was shown that this inactivation process affects 45-60% of the receptor sites, depending on the membrane preparation, regardless of the agonist and N-ethylmaleimide concentrations. Approximately 50% of the receptor sites could be inactivated in the membrane preparations used for the present study. When calculated as a function of the amount of sensitive sites (B), the rate of inactivation can be obtained from the data presented in Fig. 1 . The linear relationship between In B and the preincubation time (t) is indicative for a pseudo-first-order reaction ( (18) (19) (20) . Incubation of the turkey erythrocyte membrane preparation used in Fig. 1 Specific Protection by Guanine Nucleotides. As shown in Table 2 , GTP prevented inactivation of agonist-bound receptors to the same extent as did p[NH]ppG. Protection was reversible for both nucleotides and occurred via binding to a site which, in its native form, was insensitive to N-ethylmaleimide. GTP was unable to reactivate receptors inactivated by (-)-isoproterenol plus N-ethylmaleimide. It therefore is likely that protection by both nucleotides reflects the interaction with the same membrane component.
Protection by both nucleotides was dose-dependent. Fig. 3 In series A, membranes were preincubated for a fixed period of time (15 min) at 300C, followed by washing with buffer only. 
almost equipotent in preventing the inactivation process; kob was decreased by 50% at about 1 gM nucleotide in both cases.
A dose-related protection also was conferred by ATP (Fig.  3) , although it was significantly less potent (Fig. 3 Inset) . The 100-fold higher potency of GTP and p[NH]ppG indicates that receptor protection is mediated via a guanine nucleotide-specific site in the membrane.
DISCUSSION
We have shown (13, 14) Little is known about the number of components that constitute hormone-responsive adenylate cyclase systems or about their organization in the membrane. A generally accepted model (18) suggests that the catecholamine-stimulated adenylate cyclase system is composed of the 13-adrenergic receptor, a guanine nucleotide-dependent coupling factor (4, 5) possessing a GTPase activity in turkey erythrocyte membranes (19, 20) , and the adenylate cyclase catalytic unit. According to this model, the guanine nucleotide regulation at the level of the f3-adrenergic receptor, presented in this communication, would thus occur via the coupling factor. However, comparison of the characteristics of the guanine nucleotide sites that regulate the receptor with the reported properties of the GTPase suggests that these components are not identical.
(i) The catecholamine-stimulated GTPase (coupling factor) in turkey erythrocyte membranes is, in its native form, sensitive to N-ethylmaleimide (19) . Under the same conditions (10-min pretreatment of the membranes with 2 mM N-ethylmaleimide at 300G), the receptor regulatory site is not (Table 2) .
(ii) Guanine nucleotide modulation of the affinity of the receptor for agonists, mediated through the coupling factor, is only observed after pretreatment of the membranes by agonist plus GMP (11) . However, the protective effect by guanine nucleotides described in this work does not require such agonist plus GMP pretreatment.
(iii) A kinetic analysis by Tolkovsky and Levitzki (21) indicates that the agonist-bound receptor causes adenylate cyclase stimulation in turkey erythrocyte membranes through a transient, short-lived encounter with the GTPase-adenylate cyclase complex. The full protection of the receptor by p[NH]ppG and GTP, however, is indicative of a steady interaction between the receptors and their regulatory guanine nucleotide sites.
Although final proof will require purification and characterization of all components involved in catecholamine-stimulated adenylate cyclase, the considerations reported here suggest that those guanine nucleotide sites that affect adenylate cyclase activity (coupling factor) and those that modify the receptor-N-ethylmaleimide interaction may be borne by distinct membrane components. We recently proposed (22) a model that integrates, in the receptor cyclase system, two different guanine nucleotide binding sites, one of which is the coupling factor.
Inactivation of the (-)-[3H]dihydroalprenolol binding sites by j3-adrenergic agonists and N-ethylmaleimide has been explained by an agonist-induced change of the receptor conformation, resulting in an enhanced alkylability (13, 14) . In this context, the above-mentioned ability of guanine nucleotides to abolish the inactivation process suggests that occupation of the guanine nucleotide sites results in a new conformation of the receptor that is no longer sensitive to alkylation.
At the present level it is not determined whether this guanine nucleotide site is part of the receptor molecule or is borne by a distinct membrane component. Our previous observation (23) that the affinity chromatography-purified f3-adrenergic re- (12, 13) . Instead, they allow N-ethylmaleimide to cause a time-dependent decrease in the number of (-)-[3H]-dihydroalprenolol binding sites. This inactivation process shares some properties with desensitization of f3-adrenergic receptors in other systems such as frog erythrocytes (24) and S49 lymphoma cells (25) . Both processes are induced only in the presence of agonist molecules and affect about 50% of the receptor sites. Guanine nucleotides prevent inactivation in turkey erythrocyte membranes and cause resensitization of the /3-adrenergic receptors in frog erythrocytes (24) in a reversible fashion. The inability of nucleotides to restore receptor activity in turkey erythrocyte membranes is presumably due to the irreversible nature of the alkylation. The fact that desensitization, inactivation, and protection concern 50% of the binding sites suggests that these phenomena affect the same molecules. The remaining receptors, although analogous in binding properties, must either be structurally different or be located in a protective environment.
These similarities suggest that agonist binding to the f3-adrenergic receptors triggers the same kind of molecular interactions in turkey erythrocytes as they do in frog erythrocytes and S49 lymphoma cells. The fact that desensitization cannot be demonstrated in the turkey erythrocyte system reflects a more pronounced conformational stability of the f3-adrenergic receptor. The protective effect of guanine nucleotides against N-ethylmaleimide-induced modification of the receptor is reversible ( 
